New triple therapy aims to stop high-risk myeloma from coming back
NCT ID NCT05208307
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This study tests whether a combination of three drugs—belantamab, pomalidomide, and dexamethasone—can keep high-risk myeloma from returning after a stem cell transplant. About 34 adults who have already had a transplant and are in partial remission or better will take these drugs as maintenance therapy. The goal is to see if this approach improves response rates and is safe enough for long-term use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.